GSK Temporarily Pulls European Application For Tafinlar/Mekinist Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK has withdrawn its application to market the combined use of Tafinlar and Mekinist in Europe after the region’s top drug regulator said more data were needed on trametinib to approve the combo’s use in melanoma. GSK will resubmit the dossier once it has further results from an ongoing Phase III clinical trial.
You may also be interested in...
The Next Wave For Melanoma
Melanoma therapy could take another leap forward with the development of another BRAF inhibitor, a MEK inhibitor, and late-stage trials testing combinations against both BRAF options alone.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.